See more : Orrstown Financial Services, Inc. (ORRF) Income Statement Analysis – Financial Results
Complete financial analysis of Leap Therapeutics, Inc. (LPTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Leap Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Coloplast A/S (CBHD.DE) Income Statement Analysis – Financial Results
- Intra-Cellular Therapies, Inc. (ITCI) Income Statement Analysis – Financial Results
- BAIC BluePark New Energy Technology Co.,Ltd. (600733.SS) Income Statement Analysis – Financial Results
- Leyard Optoelectronic Co., Ltd. (300296.SZ) Income Statement Analysis – Financial Results
- Current Water Technologies Inc. (WATR.V) Income Statement Analysis – Financial Results
Leap Therapeutics, Inc. (LPTX)
About Leap Therapeutics, Inc.
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.50M | 1.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 427.00K | 415.00K | 0.00 | 0.00 | 776.00K | 49.00K | 48.00K | 25.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -427.00K | -415.00K | 1.50M | 1.50M | -776.00K | -49.00K | -48.00K | -25.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 73.23M | 44.97M | 32.16M | 20.42M | 24.37M | 21.07M | 22.50M | 23.29M | 15.37M | 15.54M | 9.30M | 7.17M |
| General & Administrative | 13.81M | 11.80M | 10.77M | 9.62M | 9.09M | 8.92M | 9.85M | 4.23M | 5.72M | 4.71M | 4.57M | 1.51M |
| Selling & Marketing | -427.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.38M | 11.80M | 10.77M | 9.62M | 9.09M | 8.92M | 9.85M | 4.23M | 5.72M | 4.71M | 4.57M | 1.51M |
| Other Expenses | 0.00 | -2.05M | -1.23M | -231.00K | -132.00K | 756.00K | 0.00 | 3.12M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 87.04M | 54.71M | 41.70M | 29.81M | 33.32M | 30.00M | 32.35M | 27.52M | 21.09M | 20.25M | 13.87M | 8.68M |
| Cost & Expenses | 87.04M | 54.71M | 41.70M | 29.81M | 33.32M | 30.00M | 32.35M | 27.52M | 21.09M | 20.25M | 13.87M | 8.68M |
| Interest Income | 4.03M | 925.00K | 9.00K | 93.00K | 313.00K | 447.00K | 170.00K | 2.00K | 156.00K | 40.00K | 94.00K | 102.00K |
| Interest Expense | 0.00 | 54.00K | 41.00K | 39.00K | 23.00K | 19.00K | 121.00K | 1.23M | 18.00K | 4.37M | 0.00 | 0.00 |
| Depreciation & Amortization | 427.00K | 415.00K | 556.00K | 668.00K | 776.00K | 49.00K | 48.00K | 25.00K | 474.00K | 657.00K | 640.00K | 649.00K |
| EBITDA | -80.99M | -53.98M | -40.01M | -26.81M | -32.10M | -23.05M | -29.71M | -24.37M | -11.92M | -19.73M | -13.23M | -6.98M |
| EBITDA Ratio | 0.00% | 0.00% | -2,679.40% | -1,881.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -87.04M | -56.76M | -41.43M | -28.54M | -33.45M | -30.75M | -32.35M | -27.52M | -21.09M | -20.92M | -13.87M | -8.80M |
| Operating Income Ratio | 0.00% | 0.00% | -2,761.73% | -1,902.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.63M | 2.31M | 815.00K | 1.02M | 548.00K | 7.63M | 2.47M | 1.89M | 9.04M | -4.50M | -4.31M | 1.04M |
| Income Before Tax | -81.41M | -54.45M | -40.61M | -27.52M | -32.90M | -23.12M | -29.88M | -25.63M | -20.95M | -25.42M | -18.18M | -7.76M |
| Income Before Tax Ratio | 0.00% | 0.00% | -2,707.40% | -1,834.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 147.00K | -24.00K | -2.00K | -3.00K | 20.00K | -157.00K | 4.35M | 152.00K | 31.00K | 149.00K | 0.00 |
| Net Income | -81.41M | -54.60M | -40.59M | -27.51M | -32.90M | -23.14M | -29.73M | -25.63M | -21.10M | -25.45M | -18.32M | -7.76M |
| Net Income Ratio | 0.00% | 0.00% | -2,705.80% | -1,834.27% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.98 | -4.82 | -4.73 | -4.64 | -14.57 | -16.36 | -32.45 | -27.29 | -12.37 | -21.45 | -24.62 | -10.42 |
| EPS Diluted | -3.98 | -4.82 | -4.73 | -4.64 | -14.57 | -16.05 | -32.35 | -27.29 | -12.37 | -21.45 | -24.62 | -10.42 |
| Weighted Avg Shares Out | 20.45M | 11.32M | 8.58M | 5.93M | 2.26M | 1.41M | 916.18K | 939.24K | 1.71M | 1.19M | 744.40K | 744.40K |
| Weighted Avg Shares Out (Dil) | 20.45M | 11.32M | 8.58M | 5.93M | 2.26M | 1.44M | 918.86K | 939.24K | 1.71M | 1.19M | 744.40K | 744.40K |
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Jan. 3, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.
Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients
CAMBRIDGE, Mass. , Jan. 2, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment has been completed in the randomized controlled Part C of the DisTinGuish study evaluating DKN-01, Leap's...
Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium
CAMBRIDGE, Mass. , Dec. 11, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the Company will be presenting new data in second-line patients with advanced colorectal cancer from the...
Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference
CAMBRIDGE, Mass. , Nov. 21, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.
Leap Therapeutics Reports Third Quarter 2023 Financial Results
CAMBRIDGE, Mass. , Nov. 13, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2023.
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
NEW YORK, NY, October 24, 2023 – The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic recessions have led to a sharp decline in...
Leap Therapeutics to Participate at Upcoming Investor Conferences
CAMBRIDGE, Mass. , Sept. 5, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.
Leap Therapeutics Reports Second Quarter 2023 Financial Results
CAMBRIDGE, Mass. , Aug, 14, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for second quarter ended June 30, 2023.
Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients
CAMBRIDGE, Mass., July 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, based on the early efficacy and momentum seen in the enrollment of 33 patients with colorectal...
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting
19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient with partial response, resulting in 73% ORR in overall mITT population, including 86% ORR in PD-L1-low patients CAMBRIDGE, Mass. , May 25,...
Source: https://incomestatements.info
Category: Stock Reports